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Short running title: BSR and BHPR Guideline for the Management of Gout  
Scope and purpose 
Background to the disease 
Gout is the most common cause of inflammatory arthritis worldwide. In UK general 
practice, the overall prevalence has increased from 1.4% in 1999 to 2.49% in 20121, 
despite the availability of effective and potentially ‘curative’ urate-lowering drugs for 
more than 50 years and evidence-based British and European management 
guidelines for nearly a decade2;3. 
Clinical manifestations of gout resulting from monosodium urate (MSU) 
crystal deposition, include tophi, chronic arthritis, urolithiasis and renal disease as 
well as recurrent acute arthritis, bursitis and cellulitis. Gouty arthritis and tophi are 
associated with chronic disability, impairment of health-related quality of life 
(HRQOL)4-7, increased use of healthcare resources, and reduced productivity8. Gout 
is also frequently associated with co-morbidities such as obesity, dyslipidaemia, 
diabetes mellitus, chronic renal insufficiency, hypertension, cardiovascular disease, 
hypothyroidism, anaemia, psoriasis, chronic pulmonary diseases, depression and 
osteoarthritis1 as well as with an increase in all-cause mortality (adjusted hazard 
ratio 1.13, 95% CI 1.08 to 1.18) and urogenital malignancy1;9. 
Sustained hyperuricaemia is the single most important risk factor for the 
development of gout. Hyperuricaemia occurs secondary to reduced fractional 
clearance of uric acid in more than 90% of patients with gout10. Age, male gender, 
menopausal status in females, impairment of renal function, hypertension and the 
co-morbidities that comprise the metabolic syndrome are all risk factors for incident 
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gout associated with decreased excretion of uric acid, as are the use of diuretic and 
many antihypertensive drugs, ciclosporin, low-dose aspirin, alcohol consumption  
and lead exposure. Tophi and chronic arthritis11, alcohol consumption12 and recent 
use of diuretic drugs13 are important risk factors for recurring flares. 
Genome-wide association studies have identified a number of genes coding 
for urate anion transporters expressed in the proximal renal tubular epithelium, but 
these account for less than 5% of the variation in serum urate14. Serum urate levels 
are influenced by dietary intake and synthesis as well as by renal excretion. Diets 
high in red meat or seafood, and increased consumption of beer, spirits and 
fructose- or sugar-sweetened soft drinks are established risk factors for developing 
gout15-17. Single gene disorders associated with urate overproduction, 
hyperuricaemia and accelerated purine synthesis de novo (such as glycogen storage 
diseases and Lesch-Nyhan syndrome) are very rare causes of primary gout. Diseases 
(such as lympho- and myeloproliferative disorders and severe exfoliative psoriasis) 
and drugs (such as cytotoxics, vitamin B12 and ethanol) associated with increased 
cellular turnover and destruction can lead to secondary hyperuricaemia and gout.18 
The identification of monosodium urate (MSU) crystals in joint and tissue samples 
remains the ‘gold standard’ for the diagnosis of gout. Although identification of urate 
deposits by dual-energy computed tomography (DECT)19 and ultrasound20 are being 
used increasingly as an aid to the diagnosis of gout in research and hospital practice, 
joint aspiration or imaging to confirm crystal presence are rarely undertaken in 
primary care settings where the majority of patients with gout are managed. For 
diagnosis in clinical practice, clinical scores, without imaging or synovial fluid 
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analysis, have been proposed21 which include consideration of the patient’s history 
and co-morbidities. 
 
Need for revised management guideline 
The British Society for Rheumatology/British Health Professionals in Rheumatology 
(BSR/BHPR) guideline for the management of gout was published in 20072. There are 
four broad reasons why a revised and updated guideline is now required. First, new 
pharmaceutical treatment options have become available and the evidence base for 
the efficacy and safety of available drugs has expanded. Second, the incidence, 
prevalence and severity of gout has increased1 despite the availability of safe, 
effective and potentially ‘curative’ therapy. Third, research studies and audits have 
consistently shown that fewer than 50% of patients with gout seen in General 
Practice receive urate-lowering therapy (ULT)22-25 and that many patients with gout 
being treated with ULT in both primary1;26 and secondary care27,28 do not achieve 
reductions of serum uric acid levels (sUA) to the target level recommended in the 
BSR/BHPR (300 µmol/L) or EULAR (360 µmol/L) guidelines. Finally, as evidence has 
accumulated that the provision of information to patients with gout is sub-optimal29 
and qualitative studies have begun to define a range of patient and provider barriers 
to effective care30-32, preliminary data are emerging which demonstrate that these 
barriers can be overcome, and outcomes improved, with better provision of 
information and a package of care based on guideline recommendations33. 
 
Other guidelines available 
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Recently published guidelines include the 2012 American College of Rheumatology 
Guidelines for the Management of Gout34,35 and the 2013 evidence-based 
recommendations for the diagnosis and management of gout by a multinational 
panel of rheumatologists participating in the 3e initiative36. Other National and 
Regional guidelines include the US Government 2014 Agency for Healthcare 
Research and Quality (AHRQ) Guidelines for the Diagnosis and Management of 
Gout37,38, and the Australian and New Zealand39 and Portuguese40 recommendations 
for the diagnosis and management of gout which arose from the 3e initiative.36 
Updated EULAR recommendations for the management of gout will be published in 
2016.  
 
Objective 
This guideline aims to offer revised and updated, concise, patient-focussed, 
evidence-based, expert recommendations for the management of gout in the UK.  
 
Target Audience 
The guideline has been developed to provide assistance to doctors and allied health 
professionals who treat and manage patients with gout in primary care and hospital 
practice. The guideline should also provide a helpful resource for patients and those 
responsible for commissioning care for patients with gout in the NHS. 
 
Areas that the guideline does not cover 
Evidence-based recommendations for the diagnosis and investigation of gout are not 
included in this guideline. Some recommendations for the diagnosis of gout are 
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addressed in the recent 3e recommendations for the diagnosis and  management of 
gout36 and EULAR recommendations for the diagnosis of gout3 are in the process of 
being updated.41   
 
Stakeholder involvement 
The guideline has been developed by a Multidisciplinary Working Group of 
rheumatologists (MH, MD, KJ, GN, ER), general practitioners (GD, CM), secondary 
care physicians with specialist experience in general internal medicine, clinical 
pharmacology (TM) and nephrology (SC), allied health professionals (AC, WJ), lay 
patients (HF, AP) and an epidemiologist with expertise in evidence-based medicine 
(WZ),  on behalf of the BSR/BHPR Standards, Audit and Guidelines Working Group 
(SAGWG). The draft guideline was presented and discussed in open session by a 
multidisciplinary audience at the annual scientific meetings of the BSR in 2014 and 
2016. The consensus recommendations were developed without any input from, or 
consultation with, any pharmaceutical company and potential conflicts of interest of 
all members of the working group have been fully declared. This guideline has been 
reviewed and endorsed by the Royal College of General Practitioners (RCGP). 
 
Rigour of development 
Scope of the guideline and strategy for guideline development 
The scope of the revised guideline and the key clinical management questions that 
needed to be addressed were agreed by consensus at an initial face-to-face meeting 
of the guideline working group after detailed review of the published guideline and 
results of a systematic literature review. Seventeen clinical management questions 
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(Table I) were subsequently subjected to additional focussed systematic literature 
searches after transposition into 20 questions in Population, Comparator, Outcome, 
Time (PICOT) format42. 
 
Systematic literature search 
Systematic literature searches were undertaken by MH using Medline 1946 to 
present, Embase 1974 to present, PubMed from inception to present, the Cochrane 
Controlled Trials Register from inception to present and the ISI Web of Science and 
AMED databases 1985 to present. An initial literature search in March/April 2012 
was updated in June 2015 (see appendix 1 for search strategy). 
 
Inclusion criteria 
Articles included were systematic reviews, randomised controlled trials (RCTs), 
uncontrolled trials, observational studies including cohort, case-control, and cross-
sectional studies, or those where economic evaluation was made. 
 
Exclusion criteria 
Editorials, commentaries, conference abstracts and non-evidence based 
narrative/personal reviews were excluded. Studies of hyperuricaemia were included 
only if they related to the management of gout. 
 
Delphi exercise to generate consensus recommendations 
Concise consensus recommendations for the management of gout were developed. 
Members of the guideline working group were asked to generate a comprehensive 
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list of propositions for the management of gout based on available research 
evidence and their own clinical expertise after reviewing the published 
recommendations and the results of the systematic literature reviews. Following 
elimination of closely similar and overlapping recommendations, a preliminary list of 
51 proposed recommendations included 13 for the management of acute gout, 15 
recommendations relating to education, diet and lifestyle modification and 23 
propositions for the management of recurrent, inter-critical and chronic gout. 
Consensus for 30 revised draft recommendations was reached after 3 rounds of a 
Delphi exercise conducted by email in which propositions with >60% of votes were 
accepted, those with <20% rejected and those attracting between 20 and 60% of 
votes reconsidered after amalgamations and minor rewording. The draft 
recommendations were presented for discussion and feedback at the annual 
scientific meeting of the BSR in 2014. Final consensus on the most appropriate 
wording for 21 recommendations was agreed at a second face-to-face meeting of 
the guideline working group after further minor amalgamations and discussion of 
the draft recommendations and the feedback from members of the BSR. 
 
Level of Evidence (LoE) 
The level of evidence in support of each recommendation was determined (1a: 
meta-analysis of RCTs, 1b: at least one RCT, IIa: at least one well designed controlled 
study without randomisation, IIb: at least one well designed quasi-experimental 
study, III: at least one non-experimental descriptive study eg comparative, 
correlation or case-controlled study, IV: expert committee reports, opinions and/or 
experience of respected authorities) 43. Where a superior level of evidence was 
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found, eg a systematic review for a particular intervention, preceding studies 
regarding that intervention were not further analysed. 
 
Strength of recommendation (SOR) 
The SOR for each treatment recommendation by members of the guideline 
development group was graded anonymously on a 0 – 100 mm Visual Analogue 
Scale (VAS) by those present at the final face-to-face meeting and by the others via 
email.   
The SOR for each management recommendation was based on the opinions 
of the guideline working group after considering the research evidence for efficacy, 
safety and cost-effectiveness of each treatment proposed, and the personal 
expertise of each member of the group.44 This included considerations such as the 
experts’ experience and perception of patient tolerance, acceptability and 
adherence to the treatment in question, as well as their expert knowledge of any 
logistic issues involved in the administration of the recommended treatment. 
 
A simplified algorithm (Figure 1) illustrates the suggested care pathway. 
 
Recommendations 
 
Management of Acute Attacks 
I. Educate patients to understand that attacks should be treated as soon as an 
attack occurs and ensure that patients are aware of the importance of 
continuing any established urate-lowering therapy during an attack. 
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LoE:  IV 
SOR: 90% (range 81-100) 
The strength of recommendation for educating patients to understand the 
importance of treating acute attacks of gout as early as possible is largely based on 
common sense, patient experience and expert opinion because of the severity of 
pain experienced by patients with acute gout. Reduction of pain within 24 hours 
following treatment with a non-steroidal anti-inflammatory drug (NSAID)45 and with 
colchicine46 has, however, been demonstrated in two small placebo-controlled RCTs. 
The recommendation to continue treatment with urate-lowering drugs during acute 
gout flares is based on a widespread consensus of expert opinion2,34,47, and 
qualitative studies that suggest that many patients are unaware of the need to do 
so30,31. 
 
II. Affected joints should be rested, elevated and exposed in a cool environment. 
Bed-cages and ice-packs can be effective adjuncts to management. 
LoE: Ib (ice-packs), IV (other) 
SOR: 89% (range 54-100) 
The recommendation to rest acutely affected joints is based on widespread patient 
experience and expert opinion. While there is evidence that urate crystal-induced  
experimental arthritis in dogs is aggravated by  movement and ameliorated by rest48 
there have been no RCTs of rest undertaken in patients with gout. The 
recommendation for using ice is supported by a Cochrane systematic review of a 
single small RCT (n=19) in which topical ice was added to prednisolone and 
colchicine49.  In this trial, greater pain reduction (-3.3 cm, 95%CI -5.84 to -0.82 on 10 
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cm VAS) was observed with adjunctive use of ice packs without additional adverse 
events. Ice packs may be used as safe adjuncts to pharmacological treatment for 
acute gout, or when drugs are contraindicated because of multiple active co-
morbidities. 
 
III. An NSAID at maximum dose or colchicine in doses of 500 micrograms bd-qds 
are the drugs of choice when there are no contraindications. Choice of first line 
agent will depend on patient preference, renal function and co-morbidities. 
Patients on NSAIDs or COXIBs should be co-prescribed a gastro-protective 
agent. 
LoE: Ia 
SOR: 95% (range 80-100) 
Khanna et al50 recently published a systematic review which included 30 papers 
examining the management of acute gout. Although NSAIDs are used more often 
than colchicine in general practice24, evidence that either are consistently more 
effective is lacking, so that choice should be determined by individual patient’s 
preference as well as by renal function and co-morbidities.  
The efficacy of NSAIDs is supported by a single placebo – controlled RCT of 
tenoxicam 40 mg daily45. Most RCTs have been head-to-head comparisons with no 
single agent having greater efficacy. There is, however, widespread expert consensus 
that, where there is no contraindication to do so, NSAIDs should be prescribed at 
high dose when treating patients with acute gout because of the severity of the pain 
and inflammation2,3,35. NSAIDs are, however, frequently contraindicated in patients 
with renal insufficiency, peptic ulceration or a history of previous upper 
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gastrointestinal haemorrhage or perforation. Selective cyclooxygenase (COX)-2 
inhibitors such as etoricoxib have equal efficacy and better gastrointestinal 
tolerability than non-selective NSAIDs51 but there are ongoing uncertainties about 
their relative cardiovascular and renal toxicity with chronic administration52. 
Co-prescription of gastro-protection is recommended for patients treated with 
NSAIDs in accordance with NICE clinical guidelines53. 
For colchicine, Khanna et al found 2 placebo-controlled RCTs demonstrating 
statistical reduction in pain at 24 and 48 hours46,54. Terkeltaub’s study demonstrated 
that a low-dose colchicine regimen (1.2 mg followed by 0.6 mg after 1 hour) was 
equally effective, and was associated with much less nausea, vomiting and diarrhoea, 
than a high dose regimen of 4.8mg over 6 hours. A Cochrane review of the same two 
RCTs55 also concluded that there was low quality evidence for the efficacy of low 
dose colchicine and for no additional efficacy with high doses which were 
significantly more likely to be associated with adverse effects (RR 3.00, 95% CI 1.98 
to 4.54).  In the absence of further trial evidence for the efficacy and safety of this 
proposed regimen, the BSR working group recommends treating acute gout with 
colchicine in doses of 500micrograms bd – qds when there are no contraindications 
to doing so. The maximum dosage of 500micrograms qds is, however, often limited 
by gastrointestinal side-effects, most frequently diarrhoea. Colchicine is 
contraindicated in patients with eGFR< 10mL/min/1.73m2 and doses should be 
reduced in patients with eGFR10-50 mL/min/1.73m2 and in the elderly56. Colchicine 
should also only be used with caution and at low doses in patients taking drugs 
which are potent inhibitors of cytochrome P450 3 A4 (eg cimetidine, clarithromycin, 
erythromycin, fluoxetine, ketoconazole, protease inhibitors, tolbutamide) or p-
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glycoprotein (eg clarithromycin, ciclosporin, erythromycin)57. Caution is also required 
when using colchicine in patients receiving statins, particularly in those with renal 
impairment, as there are case reports of myopathy and rhabdomyolysis following  
combined use of colchicine and statins58-60.  
 
IV. Joint aspiration and injection of a corticosteroid are highly effective in acute  
monoarticular gout and may be the treatment of choice in patients with acute 
illness and co-morbidity. A short course of oral corticosteroid or a single 
injection of an IM corticosteroid are alternatives in patients who are 
unable to tolerate NSAIDs/colchicine and in whom intra-articular injection is 
not feasible. Such systemic therapy is also appropriate for oligo- or 
polyarticular attacks of gout. 
LoE: Ib (oral),III (intraarticular, intramuscular), IV (oligo/polyarticular attacks) 
SOE: 94% (range 83-100) 
A Cochrane review in 201361 found no RCTs of intra-articular steroid use for the 
management of acute gout. However, small observational studies, expert opinion 
and clinical experience suggest that intra-articular and intramuscular steroid 
injections can be very effective treatments for acute gouty arthritis62-64.  
A Cochrane review of systemic corticosteroids65 for acute  gout included one 
randomised double-blind equivalence trial which showed that five-day courses of 
naproxen 500mg twice daily and prednisolone 35mg daily had equal efficacy66. 
 
V. In patients with acute gout where response to monotherapy is insufficient,    
combinations of treatment can be used. 
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LoE: IV 
SOR: 80% (28-100) 
This recommendation is supported only by expert opinion67. A survey in 200668 
found that the most commonly used combination agents are NSAIDs with either 
intra-articular corticosteroids, oral steroids, or colchicine.  
 
VI. Interleukin-1 inhibitors may be considered in patients who have previously not 
responded adequately to standard treatment of acute gout (although not 
approved by NICE). 
LoE: Ib (canakinumab, rilonacept), III (anakinra) 
SOR: 61% (range 8-100) 
Anakinra, canakinumab and rilonacept are three interleukin-1 (IL-1) inhibitors which 
have been investigated to some extent for the management of acute gout69-74.  
In an RCT, the monoclonal anti-human IL-1β antibody canakinumab (150 mg by sub-
cutaneous injection) showed good efficacy in reducing pain and swelling when 
compared with 40mg intramuscular triamcinolone acetonide69,70. Canakinumab is 
licenced for use in Europe by the EMA but not in the US by the FDA because of 
uncertainty about its risk/benefit ratio. There are currently no published RCTs for the 
use of anakinra, an IL-1 receptor antagonist, in patients with gout. However, an open 
label study using 100 mg sc on 3 consecutive days demonstrated pain relief in 
patients with gout who could not tolerate or had failed conventional treatment72 
and a retrospective review of its use off-label in 26 patients suggested that it could 
be an effective and safe alternative treatment for acute gouty arthritis in medically 
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complex hospitalised patients who fail or cannot undergo more conventional 
therapy73. 
These findings and ongoing uncertainty concerning the efficacy and safety of IL-1  
inhibitors are reflected in a recent Cochrane review74. Neither anakinra, 
canakinumab nor rilonacept are approved by NICE for use in the treatment of acute 
gout. Prescribers in the UK should be aware of the potential need to obtain approval 
for an individual funding request before these drugs should be used.  
 
Modification of lifestyle and risk factors 
VII. If diuretic drugs are being used to treat hypertension rather than heart failure, 
an alternative antihypertensive agent can be considered as long as blood 
pressure is controlled. 
LoE: IV 
SOR: 91% (range 85-100) 
Thiazide and loop diuretics are used for a number of indications including the 
management of hypertension, heart failure and other causes of fluid overload. 
Whilst diuretics have been found to be associated with an increased risk of gout with 
a rate ratio of 11.8 (95% CI 5.2-27.0)75, blood pressure control may require a number 
of agents and often includes a diuretic76. A systematic review published in 201277 
attempted to assess the risk, but as the number of studies was few, it concluded that 
there was insufficient evidence to recommend the discontinuation of diuretics 
across all indications in patients with gout. A recent population-based case-control 
study using the General Practice Research Database demonstrated that while the 
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use of thiazide and loop diuretics were associated with the development of incident 
gout, the use of potassium-sparing diuretics was not78.  
 
VIII. All patients with gout should be given verbal and written information about: 
the causes and consequences of gout and hyperuricaemia; how to manage 
acute attacks; lifestyle advice about diet, alcohol consumption and obesity; 
and the rationale, aims and use of urate-lowering therapy to target urate 
levels. Management should be individualised and take into account co-
morbidities and concurrent medications. Illness perceptions and potential 
barriers to care should be discussed. 
LoE: IIb 
SOR: 96% (range 83-100) 
There is growing evidence regarding the importance of education in gout. An 
observational, proof of concept, study33 has demonstrated how education and 
individualised lifestyle advice along with urate-lowering therapy can achieve 
therapeutic targets. In this study of 106 participants, 92% achieved the therapeutic 
target, adherence at one year was excellent, and there were improvements in pain 
and other patient-centred outcomes. 
Qualitative studies30 suggest that an inadequate understanding of the causes 
and consequences of gout, belief that it is only a man’s disease, and a stereotypical 
view of gout as being entirely self-inflicted through lifestyle abuse are important 
barriers to care. This may result in gout sufferers being hesitant in seeking medical 
advice and adhering to pharmacological treatments that are not well explained. 
Other studies have shown that such negative views about gout and its treatment are 
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associated with lower adherence to ULT and sub-optimal control of disease32,79,80. 
Patients who do not, or cannot, adhere to prescribed urate-lowering therapy are 
more likely to experience more gout attacks more frequently and in more joints. 
Such factors, as well as comorbid disease, have been found to be associated with 
poorer health-related quality of life (HRQOL)6. While patients are frequently 
interested in details of the influence of dietary constituents, they commonly also 
have important concerns relating to drug safety and drug interactions which are 
seldom adequately discussed31.  
 
IX. In overweight patients, dietary modification to achieve a gradual reduction in 
body weight and subsequent maintenance should be encouraged. Diet and 
exercise should be discussed with all patients with gout, and a well-balanced 
diet low in fat and added sugars, and high in vegetables and fibre should be 
encouraged: sugar sweetened soft drinks containing fructose should be 
avoided; excessive intake of alcoholic drinks and high purine foods should be 
avoided; inclusion of skimmed milk and/or low fat yoghurt, soy beans and 
vegetable sources of protein and cherries, in the diet should be encouraged. 
LoE: I (vitamin C and skimmed milk), III (others) 
SOR: 92% (range 80-100) 
A recent systematic review of predominantly observational studies81 identified a 
number of modifiable dietary factors which were associated with gout. Excessive 
consumption of meat, seafood, alcoholic drinks (especially beer and spirits), sugar-
sweetened soft drinks and fructose-containing foods are all significant risk factors for 
incident gout. Episodic excessive alcohol consumption, regardless of type of alcohol 
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containing beverage, is also associated with an increased risk of recurrent gout 
attacks82. Low-fat dairy intake, folate intake, coffee consumption and diets high in 
dietary fibre appear to be associated with a reduced risk of incident gout as well as a 
reduction in risk of recurrent gout flares in some, but not all cases83. Fruit 
consumption has been found beneficial and this may be related to consumption of 
vitamin C (see recommendation 19).  
The urate-lowering effect of cherry was previously reported in healthy 
women84. A case-crossover study conducted in 633 subjects with gout85 found that 
consumption of cherry and cherry extract were associated with a statistically 
significant 35% lower risk of gout attacks when compared with no cherry intake. 
When cherry intake was combined with allopurinol use, the risk of gout attacks was 
75% lower than during periods without either exposure (OR 0.25, 95% CI 0.15-0.42). 
A Cochrane systematic review of the efficacy and safety of dietary 
supplements in patients with gout found only two RCTs, one for skimmed milk 
powder (SMP) enriched with glycomacropeptides (n=120) and the other for vitamin 
C (n=40)86. Pain from self-reported flares was marginally less in those receiving 
enriched, compared with unenriched, SMP (mean difference -1.03, 95%CI -1.96 to -
0.10), but enriched SMP was no better in reducing the mean number of acute 
attacks or the sUA. Vitamin C (500 mg/day for 8 weeks) reduced the sUA (-0.014 
mmol/L) much less than allopurinol (-0.118 mmol/L) in patients with gout; and also 
less than the mean reduction of 0.02 mmol/L reported in the meta analysis of 13 
RCTs of vitamin C administration in patients with hyperuricaemia who did not have 
gout87. Vitamin C supplementation in this modest dose does not appear to have a 
clinically significant uricosuric effect in patients with gout87. It is certainly insufficient 
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for use as monotherapy and a trial suggested that its efficacy as a urate lowering 
agent, even when used as an adjunct to standard ULT with allopurinol, was 
minimal.88  
 
X. Patients with gout and a history of urolithiasis should be encouraged to 
drink >2litres of water daily and avoid dehydration. Alkalinisation of the urine 
with potassium citrate (60mEq/day) should be considered in recurrent stone 
formers  
LoE: IV 
SOR: 57% (range 17-100) 
While there are no published trials of prevention of urolithiasis in patients with gout 
and recurrent stone formation, there have been two recent systematic reviews and 
meta-analyses of RCTs of medical management of recurrent urolithiasis in all 
adults89,90. There is moderate strength evidence from relatively poor quality RCTs for 
risk reduction with increased fluid intake (RR 0.45, 95% CI 0.24-0.84) and further 
reduction of risk with additional therapy with citrates (RR 0.25, 95% CI 0.14-0.44). 
 
XI. Cardiovascular risk factors and co-morbid conditions such as cigarette smoking, 
hypertension, diabetes mellitus, dyslipidaemia, obesity and renal disease 
should be screened for in all patients with gout, reviewed at least annually and 
managed appropriately 
LoE: III 
SOR: 90% (range 77-100) 
20 
 
Co-morbidities associated with gout are well recognised81,91,92. The need to manage 
these co-morbidities is also recognised but at present no prescriptive guidance exists. 
An RCT found that allopurinol slows the progression of renal disease in patients with 
chronic kidney disease and hyperuricaemia93. The importance of screening for 
comorbidities is highlighted by a recent population-based study which has 
demonstrated gout to be an independent risk factor for mortality from coronary 
heart disease and renal disease94. 
 
Optimal use of urate-lowering therapies 
XII. The option of ULT should be explained to patients when the diagnosis is 
confirmed and they are being given information about gout. Patients should 
be fully involved in the decision as to when to commence ULT. The importance 
of taking ULT regularly and continually to prevent the return of gout attacks 
should be explained. Patients should be supported during the process of 
lowering their serum uric acid levels as it can cause an increase in gout flares 
during this time. 
LoE: Ib 
SOR: 94% (range 82-100) 
Reasons for full patient involvement have been discussed earlier in this guideline and 
are supported by preliminary evidence from a proof of concept study33. Poor patient 
understanding of the need for ULT is not confined to the UK and has been 
documented in a large population-based observational study in the US80, in a survey 
conducted in South China95 and in a focus group qualitative study in New Zealand 
Maoris96. 
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XIII. Urate lowering therapy should be discussed and offered to all patients who 
have a diagnosis of gout. ULT should particularly be advised in patients with: 
recurring attacks (≥2 attacks in 12 months); tophi; chronic gouty arthritis; joint 
damage; renal impairment (eGFR<60ml/min); a history of urolithiasis; diuretic 
therapy use; primary gout starting at a young age. 
LoE: Ia (attacks, tophi, chronic gouty arthritis, joint damage, renal impairment), III 
(urolithiasis), IV (diuretics, young age) 
SOR: 95% (range 82-100)  
Research evidence supporting the treatment gout with ULT has increased 
considerably in the last decade. Treatment of patients with recurring attacks, tophi 
and chronic gouty arthritis is supported by three systematic reviews and meta-
analyses97-99. However, the recommendation to consider treatment with ULT in all 
patients with gout is only based on expert opinion and increasing imaging evidence 
that gout is a chronic crystal deposition disease even at the time of the first attack100. 
For patients known to have other pre-existing risk factors or co-morbidities when 
presenting with the first episode of gout, such consideration is particularly pertinent. 
The length of time between the first and subsequent episode of gout can vary 
considerably between individuals, but typically is less than 2 years. Over time, the 
inter-critical periods shorten and as good practice in patient education, it is worth 
having the discussion about treatment early in the course of the disease, always 
bearing in mind that this potentially ‘curable’ condition can have a significant impact 
on patient quality of life if left untreated5;6. It is not recommended that 
asymptomatic hyperuricaemia is treated. However, the wisdom of the 
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recommendation that commencement of ULT should at least be considered after the 
first attack of gout is supported by observational data from the UK Clinical Practice 
Datalink which showed that less than half the patients with gout eligible for ULT 
were offered treatment23.  
Earlier recommendations to offer treatment with ULT only to gout patients 
with recurring acute attacks were supported by a health economic study in a 
Canadian healthcare setting which showed that only 62% of patients with gout had a 
second attack within one year and that treatment with ULT only became cost-
effective (cost saving) in patients suffering more than 3 attacks per year101. This 
study, however, does not take into account the ongoing ‘silent’ deposition of crystals 
and the significant pain experienced by patients with each attack. Clinical experience 
and epidemiological studies102,103 also show that the risk of gout attacks rises sharply 
when the serum urate is very high (>500 µmol/L). However, the decision as to when 
to start ULT in any individual will also be influenced by the patient’s co-morbidities, 
any potential contraindications, intolerance or drug interactions, as well as by 
consideration of the overall balance of risks and benefits and the patient’s wishes. 
A large population-based study has demonstrated that gout is an 
independent risk factor for mortality and specifically for death due to coronary heart 
disease and renal disease94. Gout is a risk factor for the development of end-stage 
renal failure104 and hyperuricaemia is an independent risk factor for renal 
impairment105. There is now evidence from RCTs that allopurinol slows progression 
in hyperuricaemic  patients with CKD93,106 and a recently published systematic review 
supports the concept that treating gout with ULT improves renal function55. 
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Treatment of patients with gout and urolithiasis with ULT is supported by 
observational studies107, while the recommendation to consider ULT in patients 
taking diuretic drugs is supported by 3 cohort studies and 4 case-control studies 
which demonstrated higher risks of gouty arthritis in users compared with nonusers 
of diuretics77.  
The recommendation to treat patients with primary gout at an early age with 
ULT is largely based on expert opinion. A number of rare monogenic disorders 
associated with inborn errors of purine metabolism108,109, glycogen storage 
diseases110 or uromodulin mutations associated with decreased fractional urate 
excretion111 can result in the development of gout at an early age. A retrospective 
study of patients seen by rheumatologists in Taiwan suggested that the age at which 
gout presents was falling112 and heritability accounts for 35% of gout risk in men and 
17% in women in Taiwan1. Common dysfunctional variants in the ABC G2 urate 
transporter may be important causes of early onset gout in Japanese males113 and in 
Han Chinese114 but evidence from twin studies in the US suggest that while genetic 
factors have an important influence on serum urate levels and hyperuricaemia, 
lifestyle and environmental factors are more important risk factors for primary gout, 
outside the context of the rare single gene disorders115. 
 
XIV. Commencement of ULT is best delayed until inflammation has settled as ULT 
is better discussed when the patient is not in pain.  
LoE: IV 
SOR: 94% (range 87-100) 
24 
 
Although a small RCT has shown that commencement of allopurinol during an acute 
attack was not associated with a significant increase in daily pain, recurrent flares or 
inflammatory markers116 the working group thought that postponing detailed 
discussion of long term ULT until a time when the patient was no longer in pain 
would allow the information to be better absorbed. However, in patients in whom 
attacks are so frequent to make this difficult, the findings of this trial support 
initiation of ULT before inflammation has resolved.  
 
XV. The initial aim of ULT is to reduce and maintain the sUA at or below a target 
level of 300 µmol/L to prevent further urate crystal formation and to dissolve 
away existing crystals. The lower the sUA the greater the velocity of crystal 
elimination. After some years of successful treatment, when tophi have 
resolved and the patient remains free of symptoms, the dose of ULT can be 
adjusted to maintain the sUA at or below a less stringent target of 360μmol/l 
to avoid further crystal deposition and the possibility of adverse effects that 
may be associated with a very low sUA. 
LoE: III (sUA target<300 µmol/L), IV (subsequent dose adjustment to sUA<360 
µmol/L) 
SOR: 97% (range 90-100) 
The target sUA of <300μmol/l recommended in the previous BSR/BHPR guideline2 
remains the recommended target to prevent crystal formation and recurrent 
flares117. Evidence that greater velocity of crystal elimination is associated with a 
lower sUA is derived from observational data118,119. The recommendation for ULT 
dose reduction to the less stringent target of sUA below 360 µmol/L once the patient 
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is stable to avoid further crystal deposition and the possibility of adverse effects that 
may be associated with a very low sUA is based on expert opinion, a reasoned 
proposal for such a two stage approach119 and caution in the light of studies which 
have shown a possible association between low sUA levels and progression of 
neurodegenerative disorders such as Parkinson’s disease120, dementia121, 
Huntingdon’s disease122 and amyotrophic lateral sclerosis123.  One study showed an 
increased risk of incident Parkinson’s disease in men with sUA <300µmol/L 
compared with those with sUA 300-500µmol/L124. 
 
XVI. Allopurinol is the recommended first-line ULT to consider. It should be started 
at a low dose (50-100mg daily) and the dose then increased in 100mg 
increments approximately every 4 weeks until the sUA target has been 
achieved (maximum dose 900mg). In patients with renal impairment smaller 
increments (50mg) should be used and the maximum dose will be lower, but 
target urate levels should be the same. 
LoE: Ib (dose escalation),III (dose adjustment for renal function) 
SOR: 97% (range 88-100) 
Research evidence for the efficacy and safety of allopurinol has been studied in a 
recent systematic review125. Eleven trials involving a total of 4531 patients compared 
allopurinol in various doses with placebo (two trials); febuxostat (four trials); 
benzbromarone (two trials); colchicine (one trial); probenecid (one trial); continuous 
versus intermittent allopurinol (one trial) and different doses of allopurinol (one 
trial). In double blind RCTs, allopurinol given in a fixed dose of 300mg daily was more 
effective than placebo126 but less effective than febuxostat 80 mg or 120 mg 
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daily126,127. However, these trials, and observational studies of gout being treated in 
UK General Practice,33 have shown that many patients do not achieve reductions of 
sUA to target levels recommended by the BSR (300 µmol/L)2 or EULAR (360 µmol/L)3 
when treated with allopurinol in doses of 300mg or less daily. Recent data from the 
Nottingham proof of concept study33 and from the FAST trial128 have confirmed that 
gradual up-titration of allopurinol is effective in lowering sUA to target levels and 
generally well tolerated. The median dose of allopurinol found to be required to 
achieve the less stringent therapeutic sUA target of ≤ 360 µmol/L in >90% of the 
Nottingham patients was 400mg/day. While we await direct comparison between 
allopurinol and febuxostat (and other ULTs) using recommended, best practice, up-
titration regimens rather than fixed doses, allopurinol should remain the first option. 
The recommendation that allopurinol should be the first-line ULT to consider is 
further supported by health economic studies129,130. 
Although well tolerated by the majority of patients, allopurinol is rarely  
(~0.1-0.4%) associated with severe, potentially life-threatening, cutaneous adverse 
reactions (SCAR) including toxic epidermal necrolysis (TEN), hypersensitivity drug 
reactions with rash, eosinophilia and systemic symptoms (DRESS) or Stevens-
Johnson syndrome with vasculitis, liver and renal toxicity131. Allopurinol should not 
be used in people carrying the variant allele HLA-B*5801132 as the risk of SCAR during 
treatment with allopurinol is greatly increased (OR 73)133. Screening patients of 
Korean, Han Chinese and Thai descent for HLA-B*5801 before considering ULT with 
allopurinol has been recommended35 because of the high frequency (6 – 12%) of this 
allele in these ethnic groups compared with < 2% in Caucasian populations. 
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Based on reports of a relationship between the use of full dose allopurinol 
and the development of allopurinol hypersensitivity in patients with renal 
impairment previous recommendations were to dose allopurinol according to 
creatinine clearance (CrCl)134. Unfortunately subsequent observational studies 
showed that dose-adjustment according to CrCl seldom resulted in adequate 
reduction of sUA in patients with gout and renal insufficiency135, and a case-
controlled study showed no evidence of a reduction in frequency of allopurinol 
hypersensitivity in patients dosed according to CrCl136. More recently, studies by 
Stamp et al have suggested that lowering the starting dose of allopurinol 
appropriate to the level of renal function (Table 2) reduces the risk of allopurinol 
hypersensitivity137, and that subsequent gradual increase in the dose above the dose 
based on CrCl resulted in reduction of sUA to target levels in most patients without 
any increase in toxicity138. 
 
XVII. Febuxostat can be used as an alternative second line XO inhibitor for patients 
in whom allopurinol is not tolerated or whose renal impairment prevents 
allopurinol dose escalation sufficient to achieve the therapeutic target. Start 
with a dose of 80mg daily and, if necessary, increase after 4 weeks to 120mg 
daily, to achieve therapeutic target.  
LoE: Ia 
SOR: 90% (range 63-100) 
Systematic reviews and meta-analyses97,99 of randomised controlled trials126,127,139, 
amongst other RCTs, have demonstrated the efficacy of febuxostat in reducing sUA 
levels, and reducing the risk of gout flares. When compared to a fixed dose of 300mg 
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of allopurinol, febuxostat (80mg and 120 mg/day) was more effective in reducing the 
sUA to <360mmol/L (RR 1.56; 95% CI 1.22-2.00)) but not the risk of gout flares (RR 
1.16 95% CI 1.03-1.30)97. There was heterogeneity in the dosages of febuxostat and 
allopurinol used, the length of time patients had had gout, the length of follow up, 
and whether prophylaxis was used.  
Febuxostat is generally well-tolerated and can be used in doses of 80mg or 
120mg daily in elderly patients140 and others with mild – moderate renal impairment 
(GFR > 30 ml/ min/ 1.73m2). There are currently insufficient data available on its use 
in patients with more severe CKD. Severe cutaneous hypersensitivity reactions to 
febuxostat141,144 are very unusual but the risk of SCAR or DRESS with febuxostat in 
patients with previous allopurinol hypersensitivity has still to be established. 
Treatment with febuxostat in patients with ischaemic heart disease or congestive 
cardiac failure is currently not recommended143,144 but large scale RCTs are currently 
in progress in Europe128 and North America145 to establish and compare the 
cardiovascular safety of febuxostat and allopurinol in patients with gout, high 
cardiovascular risk and co-morbidities.  
Health economic studies have shown that febuxostat is cost-effective as a 
second-line ULT129,130.  In the UK, NICE have recommended the use of febuxostat 
only when allopurinol is contraindicated or not tolerated144 while the Scottish 
Medicines Consortium (SMC) accepts febuxostat as a suitable second-line ULT when 
treatment with allopurinol is inadequate, not tolerated, or contraindicated146. 
 
XVIII. Uricosuric agents can be used in patients who are resistant to, or intolerant of, 
xanthine-oxidase inhibitors. The preferred drugs are sulfinpyrazone (200-800 
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mg/day) or probenecid (500-2000mg/day) in patients with normal or mildly 
impaired renal function, or benzbromarone (50-200mg/day) in patients with 
mild-moderate renal insufficiency. 
LoE: Ia 
SOR: 92% (range 82-100) 
Uricosuric drugs were the first agents to be used for ULT more than 60 years ago147. 
Their efficacy and safety for ULT is supported by a recent systematic review and 
meta-analysis148 of two RCTs comparing benzbromarone with allopurinol, two RCTs 
comparing benzbromarone with probenecid and one non-randomised case-
controlled trial (CCT) comparing probenecid with allopurinol; and a cohort study 
examining probenecid149, but there have been no placebo-controlled RCTs of the 
three drugs which are currently approved for use as ULT in patients with gout in 
Europe (sulfinpyrazone 200-800mg od, probenecid 250-500mg qds, benzbromarone 
50-200mg od ). In an RCT of patients who did not tolerate allopurinol 300mg/day 
well or achieve target sUA, benzbromarone 200mg/day was found to be more 
effective and better tolerated than probenecid 2g/day150, and benzbromarone 
200mg daily was approximately equipotent with allopurinol 600mg/day in lowering 
sUA to target in another RCT151.  All uricosurics are contraindicated or need to be 
used with great caution in patients with urolithiasis or severe renal impairment. 
Clinical experience indicates that sulfinpyrazone and probenecid have limited 
efficacy in patients with mild or moderate renal insufficiency (GFR < 60 ml/min) but 
benzbromarone has been shown to maintain uricosuric efficacy when the GFR is as 
low as 20ml/min152. Probenecid and benzbromarone are only available for the 
treatment of patients with gout in the UK on a named patient basis, and patients 
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requiring these unlicensed drugs should be under the care of a rheumatologist. The 
use of benzbromarone was restricted in Europe following rare reports of severe 
hepatotoxicity, mainly from Asian countries. Patients treated with benzbromarone 
should have liver function tests monitored but the risk of serious hepatotoxicity in 
patients receiving the benzbromarone in Europe is estimated as approximately 1 in 
17,000153.  
 
XIX. Losartan and fenofibrate should not be used as a primary ULT but where 
treatment for hypertension or dyslipidaemia, respectively, are required, they 
may be considered as they have a weak uricosuric effect. Vitamin C 
supplements (500mg – 1500mg daily) also have a weak uricosuric effect. 
LoE: III 
SOR: 89% (range 63-100) 
Unlike ACE inhibitors, beta blockers and other angiotensin II receptor blockers used 
for treating hypertension, losartan 50 mg od has been shown to have mild uricosuric 
effects in patients with gout154; and the use of  losartan was associated with a 
significantly reduced risk of incident gout (RR 0.81, 95% confidence interval 0.70 to 
0.94) in a large community-based UK case-control study using data from The Health 
Improvement Network (THIN) 155. 
The lipid-lowering agent fenofibrate has been shown to be uricosuric156 and 
to have a modest additional urate-lowering effect in gout patients being treated with 
allopurinol157,158. Losartan (50mg od) and fenofibrate (300mg od) were both found to 
have some additional urate-lowering efficacy when administered to gout patients 
receiving ULT with allopurinol or benzbromarone in one small study159. 
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A meta-analysis of 13 RCTs found that sUA can be lowered by vitamin C 
supplementation in patients without gout and that sUA reductions were greater in 
trials administering vitamin C >500mg/day87.  A single RCT in patients with gout 
showed that vitamin C (500 mg/day for 8 weeks) reduced the sUA (-0.014 mmol/L) 
much less than allopurinol (-0.118 mmol/L)88. Vitamin C supplements in this modest 
dose only have a very weak uricosuric effect in people with gout which is insufficient 
for it to be used as substitute monotherapy for allopurinol or other licenced ULT. 
Moreover, the study of Stamp suggests that in this dosage it is also unlikely to be a 
clinically useful adjunct to standard ULT with allopurinol88. No studies have been 
undertaken to assess whether vitamin C supplementation is effective in reducing the 
incidence of recurrent gout attacks. 
 
XX. A uricosuric agent can be used in combination with a xanthine oxidase 
inhibitor in patients who do not achieve a therapeutic serum urate target with 
optimal doses of monotherapy. 
LoE: III 
SOR: 88% (range 71-100) 
Enhancement of uric acid excretion and reduction of sUA in patients with 
tophaceous gout by combined treatment with sulfinpyrazone and allopurinol was 
first demonstrated nearly 50 years ago160. Observational studies by Perez-Ruiz and 
colleagues have shown that the velocity of tophus volume reduction in patients with 
chronic tophaceous gout could be accelerated with more profound reduction of sUA 
by combined treatment with allopurinol and benzbromarone118. They subsequently 
demonstrated that even gout patients that are primary overproducers of urate, with 
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apparently increased urine uric acid excretion, also have evidence of defective 
fractional urate clearance161 and may therefore respond to addition of a uricosuric 
drug if their sUA is not reduced to target levels with a xanthine oxidase inhibitor 
alone. More recent observational studies have also shown that combined treatment 
with allopurinol and benzbromarone was more effective in lowering sUA than either 
agent alone162. A recent single case report has demonstrated effective lowering of 
sUA in a patient with gout and chronic renal failure with addition of a combination of 
allopurinol and febuxostat to benzbromarone when combination of a single xanthine 
oxidase inhibitor with benzbromarone was ineffective163. Most recently phase III 
trials of a new selective uric acid reabsorption inhibitor, lesinurad, have shown it to 
be effective in doses of 200mg od and 400mg od in lowering the sUA to target levels 
in combination with allopurinol in patients with gout that have not responded 
adequately to allopurinol ≥300mg daily (≥200mg in moderate renal impairment)164. 
Its use for this indication has recently been given FDA and EMA approval and 
marketing authorisation. 
 
XXI. Colchicine 500micrograms bd or od should be considered as prophylaxis 
against acute attacks resulting from initiation or up-titration of any ULT and 
continued for up to 6 months. In patients who cannot tolerate colchicine, a 
low-dose NSAID or Coxib, with gastroprotection, can be used as an alternative 
providing there are no contraindications. 
LoE: Ib 
SOR: 86% (range 29-100) 
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Prophylaxis against acute flares in patients initiating ULT has been the subject of two 
recent systematic reviews125,165. There is more evidence from RCTs to support the 
use of colchicine, than for NSAIDs, for flare prophylaxis. In a 6-month placebo-
controlled RCT in patients with gout receiving probenecid for ULT, the flare rate was 
reduced from 6 to 2.3 flares per annum in patients receiving colchicine 
500micrograms daily166. In another 6-month placebo-controlled RCT in patients 
initiating allopurinol at a dose of 100mg od followed by up-titration in 100mg 
increments, flares occurred in 33% of patients given colchicine 500micrograms bd for 
flare prophylaxis compared with 77% of those treated with placebo167. An 
investigator-initiated re-analysis of gout flare data from the three Phase III trials of 
febuxostat found that flare prophylaxis for up to 6 months with colchicine 
600micrograms od or naproxen 250mg bd, during the initiation of ULT with 
febuxostat or allopurinol, appeared to provide greater benefit than flare prophylaxis 
for 8 weeks, with no increase in adverse events168. There is little other research 
evidence to help determine the optimal duration of prophylaxis. A systematic 
review125 identified a single RCT comparing three treatment groups given colchicine 
1000micrograms daily for 3-6 months, 7-9 months and 10-12 months169. By 12 
months, recurrent acute gout was reported by 54%, 28% and 23% respectively. 
Adverse events did not differ between the three groups. However, the risk of bias 
was high.  
Long-term prophylaxis with colchicine or NSAIDs in patients with gout always 
demands a careful consideration of the overall benefit to risk balance in individual 
patients, and especially in those with co-morbidities and potential for drug 
interactions. When using Cox-2 selective or non-selective NSAIDs the risks of upper 
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GI bleeds and cardiovascular risk should be considered, and gastro-protection with a 
proton pump inhibitor is recommended.  Although usually well-tolerated, possible 
side-effects of long-term colchicine include diarrhoea, nausea/vomiting, marrow 
suppression, myopathy, and rhabdomyolysis. 
The use of flare prophylaxis is particularly important when ULT is initiated 
with febuxostat, as the lowest available starting dose in the UK (80 mg) lowers the 
serum acid level to a greater degree than the starting dose of allopurinol (100 mg), 
and the risk of precipitating a gout flare is consequently greater97.  
There is no research evidence to support the use of corticosteroids for flare 
prophylaxis.  
IL-1 inhibitors have also been investigated for use for flare prophylaxis169-172 
but none are currently approved for this indication by the EMA or FDA and it is likely 
that the costs of these biologics will preclude their use for this indication in patients 
with gout in the UK NHS. In a phase 2 trial of various doses of canakinumab and 
colchicine 500micrograms od in over 400 patients initiating treatment with 
allopurinol, the mean number of flares per patient after 4 months was less in the 
canakinumab treated patients at all doses > 50mg but there was no evidence of a 
dose response and there were more infections in the canakinumab treated patients 
(18%) than in those given colchicine prophylaxis (12%)169. 
 
Management points in special groups 
Patients with renal insufficiency  
Chronic kidney disease (CKD) and nephrolithiasis are very common in patients with 
gout. A recent systematic review and meta-analysis of epidemiological and 
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observational studies suggested that the overall prevalence of CKD (≥stage 3; 
GFR<60ml/min/1.73m2) in patients with gout was 24% compared with 8.5% in the 
non-gouty population, and the prevalence of self-reported nephrolithiasis was 
14%174. This presents physicians with important challenges in managing patients with 
gout, and management of gout in patients with renal impairment has been the 
subject of two recent systematic reviews and a guideline from the US National 
Kidney Foundation175,176.  
For the management of acute gout, the dose of oral colchicine should be 
reduced in patients with eGFR 10-50ml/min/1.73m2 but is contraindicated in 
patients with more severe renal impairment (GFR<10ml/min/1.73m2). High dose 
NSAIDs should not be used even in patients with moderate renal impairment177,178. 
Although the efficacy of corticosteroids in those with CKD has not been evaluated in 
RCTs175, clinical experience suggests that they can be effective and safe for managing 
acute gout in patients with severe renal impairment or in other patients in whom 
colchicine and NSAIDs cannot be used. Intra-articular triamcinolone hexacetonide 
(40mg for large joint, 10-20mg for smaller joints) is often recommended if only one 
or two joints are inflamed, or a 7 – 14 day course of oral prednisolone (30 - 40mg 
tapering to nothing), if multiple joints are involved or if arthrocentesis is not possible.  
Guidelines for the use of allopurinol, febuxostat and uricosuric drugs in 
patients with renal impairment have been discussed following recommendations 16, 
17 and 18. 
Flare prophylaxis with colchicine or NSAIDs in patients with gout and renal 
insufficiency initiating ULT needs to be undertaken with great caution as the risks of 
colchicine toxicity, especially myopathy, are increased in patients with renal 
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impairment179 and NSAIDs can cause acute kidney injury and further impair renal 
function in patients with CKD180. Prophylaxis with low-dosage colchicine, adjusted for 
renal function, is believed to be a safer option than low-dose NSAIDs175,176. Based on 
pharmacokinetic data in patients with CKD181 it is suggested that there is no need for 
reduction in colchicine dosage (500micrograms od or bd) for flare prophylaxis in 
patients with mild renal insufficiency (eGFR >60ml/min/1.73m2) but the dose should 
be limited to 500micrograms od in those with a eGFR of 30-60ml/min/1.73m2 and to 
500micrograms every 2-3 days with eGFR10-30ml/min/1.73m2,182 and avoided 
altogether if eGFR<10 ml/min/1.73m2. Although it is usually recommended that 
NSAIDs should be avoided in all patients with renal impairment, a recent systematic 
review and meta-analysis of observational studies found no evidence of accelerated 
CKD progression in patients with moderate to severe renal impairment treated with 
low dose NSAIDs (OR: 0.96; 95% CI 0.86-1.07) 177.  
 
Severe refractory tophaceous gout 
Patients with severe symptomatic tophaceous gout in whom hyperuricaemia cannot 
be controlled with standard ULTs alone, or in combination, should be referred to a 
rheumatologist. Pegloticase, a polyethylene glycol modified mammalian uricase can 
be effective in such patients183,184, although not approved by NICE. The drug is 
administered by IV infusion (8mg in 250ml normal saline over 2 hours) every 2 weeks 
by physicians with experience and facilities for dealing with infusion reactions and 
patients should be pre-treated with antihistamines and steroids to reduce the risk of 
infusion reactions, in addition to low dose colchicine or NSAIDs for flare prophylaxis. 
Despite heavy pegylation, pegloticase is immunogenic. SUA should be measured 
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before each infusion, and treatment discontinued if the sUA is >360µmol/L as 
transient responders (about 50%) appear to be at increased risk for infusion 
reactions and anaphylaxis. Pegloticase is contraindicated in patients with G6PD 
deficiency because of the risk of haemolysis and extra caution is required in patients 
with congestive heart failure. Pegloticase has FDA approval and EMA marketing 
authorisation in Europe but has not been approved by NICE or the SMC because of 
concerns about toxicity and cost. Rasburicase, a recombinant Aspergillus flavus 
uricase which is licenced for the treatment and prophylaxis of tumour lysis syndrome, 
but not for gout, has also been used successfully in some patients with severe 
refractory gout185 despite its greater potential immunogenicity. Prescribers in the UK 
should be aware of the potential need to obtain approval for an individual funding 
request before these drugs should be used. 
 
In pregnancy 
Apart from patients with familial juvenile hyperuricaemic nephropathy186, gout is 
very uncommon in pre-menopausal women and in pregnancy187 and so data are 
sparse. Conservative measures including ice are safe for managing acute attacks. 
NSAIDs can be used in the mid-trimester188. Steroids are generally safe to use in 
pregnancy189 and the recommendations for lifestyle modifications including the 
dietary changes discussed previously are also safe. 
The safety data for colchicine during pregnancy are largely derived from 
studies of its use in Familial Mediteranean Fever190 although there are also some 
reports of chromosomal damage. High concentrations of colchicine can be found in 
breast milk and so colchicine is best avoided when breast feeding. 
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Allopurinol and febuxostat have not been adequately tested during 
pregnancy. Probenecid was used extensively in the past during antibiotic treatment 
of infections in pregnant women without any reported foetal toxicity. 
 
Applicability and utility 
Statement of potential organisational barriers to introduction 
Despite the increasing prevalence of gout and the availability of effective and 
potentially ‘curative’ ULT for more than 50 years, its management remains poor with 
only 40% of patients with gout ever receiving ULT.1 Inadequate provision of 
information to patients29 has been identified as one of the key barriers30-32 to 
effective management of gout. There is preliminary evidence that patient adherence 
to ULT and lowering of sUA to target levels can be achieved with better provision of 
information and a package of care based on guideline recommendations33. Effective 
provision of information and monitoring of treatment to achieve target sUA levels 
requires regular ongoing clinical review. However, anecdotal reports suggest that 
some secondary care organisations prohibit follow-up of patients with gout, insisting 
on discharge with a treatment plan to primary care where treatment is known to be 
sub-optimal. Furthermore, although approximately 20% of people presenting with 
their first attack will have a second episode within 12 months,191 patients often do 
not consult for subsequent attacks so practitioners may not be aware of recurrent 
attack frequency and the need for ULT, highlighting the case for discussing ULT early 
in the course of disease. 
 
Potential cost-implications for implementation of the guideline 
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Although there are few cost-effectiveness studies in gout, the guideline takes these 
into account. The guideline recommends allopurinol as the first-line ULT which is 
inexpensive and likely to be tolerated and effective in the vast majority of patients 
with gout. The cost-effectiveness of febuxostat as a second-line ULT has been 
established and our guidance for its use concords with its NICE and SMC 
approval.129,130,144,146 The guideline does include recommendations for unlicensed or 
non-NICE approved use of pegloticase and IL-1 inhibitors although the need to use 
these drugs is likely to be rare and  individual clinicians are advised to consider local 
arrangements for funding individual funding requests if using these drugs. 
 
Summary of changes in the revised recommendations 
This guideline contains several important changes from the 2007 BSR/BHPR 
guideline2. The importance of patient education and provision of information about 
gout and its treatment are strongly emphasised in the updated guideline 
(recommendations 1,8,9,12,13,14). It is now recommended that an NSAID or 
colchicine are both drugs of choice for acute gout when there are no 
contraindications and that the choice of first line agent should be determined by 
renal function, co-morbidities and patient preference (recommendation 3). 
Combinations of NSAIDs with corticosteroids or colchicine can be used for acute 
attacks where response to monotherapy is insufficient (recommendation 5), and 
interleukin-1 inhibitors may be considered in patients who have not responded 
adequately to standard treatment (recommendation 6). 
The revised guideline emphasises that all patients with gout should be screened 
for cardiovascular risk factors and co-morbid conditions such as cigarette smoking, 
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hypertension, diabetes mellitus, dyslipidaemia, obesity, and renal disease at least 
annually and treated appropriately (recommendation 11). It is now recommended 
that that the option of ULT should be explained and offered to all patients with gout 
as part of their education about the condition and that patients are fully involved in 
the decision as to when to commence ULT (recommendations 12 and 13). Although 
the revised guideline still recommends reduction of sUA with ULT to a target of 
300µmol/L, ULT dose adjustment to the less stringent sUA target of 360µmol/L is 
now recommended after some years of successful ULT when tophi have resolved 
and the patient remains symptom free (recommendation 15). It is now 
recommended that in patients with renal impairment the maintenance dose of 
allopurinol need not be strictly limited according to the creatinine clearance. The 
starting dose should, however, be low and then carefully increased with smaller 
increments (50mg) until the target sUA of 300µmol/L is reached (recommendation 
16). Febuxostat can be used as an alternative second-line XO inhibitor for patients in 
whom allopurinol is not tolerated or whose renal impairment prevents allopurinol 
dose escalation sufficient to achieve the therapeutic target (recommendation 17). 
For patients with severe symptomatic tophaceous gout in whom hyperuricaemia 
cannot be controlled with standard ULTs alone, or in combination, treatment with 
pegloticase can be considered by physicians with experience and facilities for dealing 
with infusion reactions. 
 
Questions for audit and recommendations for future clinical research can be found 
in appendices 2 and 3. An audit tool is available on the website of the British Society 
for Rheumatology.  
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Figure 1 Algorithm for the management of gout 
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Table I  Principal Clinical Questions considered 
1. In patients with acute gout, does the use of ice packs reduce pain? 
2. In patients with acute gout, what medication should be used to manage acute 
attacks? 
3. For patients on diuretic therapy presenting with acute gout, should diuretic 
therapy be discontinued? 
4. What are the potential patient and healthcare professional barriers to 
management of patients with gout? 
5. Is patient education effective for patients with gout and, if so, in what format? 
6. Is dietary advice effective in the management of patients with gout? 
7. In patients with gout and renal failure, should the dose of allopurinol be 
adjusted? 
8. Should patients with gout be screened for co-morbidities? 
9. In patients with hyperuricaemia or gout, when should urate-lowering therapy be 
commenced? 
10. In patients with gout, should allopurinol be used as first-line urate-lowering 
therapy? 
11. In patients with gout, should febuxostat be used as an alternative urate-
lowering therapy to allopurinol and, if so, in what situations? 
12. In patients with gout, should other medications such as benzbromarone, 
sulfinpyrazone, and probenecid be used? 
13. In patients initiating urate-lowering therapy, for how long should prophylactic 
colchicine be continued? 
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14. In patients initiating urate-lowering therapy, should canakinumab and rilonacept 
be used to prevent gout attacks? 
15. In patients with hyperuricaemia, gout and hypertension, should an angiotensin II 
blocker rather than an angiotensin-converting-enzyme blocker be used? 
16. In patients with gout and hyperlipidaemia, should fenofibrate be used as an 
adjunctive urate-lowering agent? 
17. In patients with debilitating chronic tophaceous gout refractory to oral urate- 
lowering drugs, or in whom these drugs are contraindicated, should pegloticase 
be used? 
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Table 2 Starting regime of allopurinol according to glomerular filtration rate 
(reproduced with permission from Stamp LK et al, Arthritis and 
Rheumatology, Starting dose is a risk factor for allopurinol 
hypersensitivity syndrome: a proposed safe starting dose of 
allopurinol, Volume 64, issue 8, pages 2529-2536137) 
Estimated GFR 
ml/minute/1.73m2 
Allopurinol starting dose 
<5 50mg/week 
5-15 50mg twice weekly 
16-30 50mg every 2 days 
31-45 50mg/day 
46-60 50mg and 100mg on alternate days 
61-90 100mg/day 
91-130 150mg/day 
>130 200mg/day 
GFR, glomerular filtration rate 
 
 
 
